-- Questerre Energy (QEC.TO) 週五宣布，將以 2,350 萬美元的價格出售其在阿爾伯塔省 Kakwa Central 油田的非作業少數股權。 該公司表示，此次出售價格包括 2,350 萬美元的現金支付、承擔該油田的退役負債以及履行其在運輸和加工合約項下的承諾。 該公司指出，該油田在 2026 年第一季的平均日產量約為 650 桶油當量 (boe/d)。 Questerre 預計，包括其持有 50% 權益的 Kakwa North 油田在內，其平均日產量將超過 4500 桶油當量。 執行長 Michael Binnion 表示：“此次出售增強了我們的資產負債表，且無需發行任何股權資本。我們將專注於開發其他資產，包括我們在 Kakwa North 的相鄰土地。” 該公司股票在多倫多證券交易所的最新交易價格上漲 0.02 美元，至 0.32 美元。
Price: $0.32, Change: $+0.02, Percent Change: +6.67%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.